Evidence map›Paper›PMID 38693516›Full record

ArticleJournal of translational medicine2024

Removal of endothelial surface-associated von villebrand factor suppresses accelerate datherosclerosis after myocardial infarction.

Koya Ozawa, William Packwood, Matthew A Muller, Yue Qi, Aris Xie, Oleg Varlamov, Owen J McCarty, Dominic Chung, José A López, Jonathan R Lindner

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. The Thigh Saphenous Vein Versus the Calf Saphenous Vein: Searching for the Optimal Conduit for Coronary Artery Bypass Grafting.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2025
    Observational
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Koya OzawaSydney Medical School Nepean, Faculty of Medicine and Health, Department of Cardiology, The University of Sydney, Nepean Hospital, Sydney, NSW, Australia.
William PackwoodKnight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, USA.
Matthew A MullerKnight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, USA.
Yue QiKnight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, USA.
Aris XieCardiovascular Division and Robert M. Berne Cardiovascular Research Center, University of Virginia, Box 801394, 415 Lane Rd, Charlottesville, VA, 22908, USA.
Oleg VarlamovOregon National Primate Research Center, Portland, OR, USA.
Owen J McCartyDepartment of Biomedical Engineering, Oregon Health & Science University, Portland, USA.
Dominic ChungBloodWorks Research Institute, University of Washington, Seattle, WA, USA.
José A LópezBloodWorks Research Institute, University of Washington, Seattle, WA, USA.
Jonathan R LindnerCardiovascular Division and Robert M. Berne Cardiovascular Research Center, University of Virginia, Box 801394, 415 Lane Rd, Charlottesville, VA, 22908, USA. jlindner@virginia.edu.ORCID 0000-0003-2604-5277
Oregon Health & Science University · USUniversity of Virginia · USUniversity of Washington · USOregon National Primate Research Center · USThe University of Sydney · AU

Funding

Targeted CEU Imaging of Atherosclerosis and AngiogenesisR01HL078610 · NHLBI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI LINDNER, JONATHAN R · 2004 to 2022
$6.8M
Molecular and Translational Studies in Hematologic DisordersR35HL145262 · NHLBI · BLOODWORKS · PI LOPEZ, JOSE ARON · 2019 to 2024
$6.5M
Augmentation of Tissue Perfusion with Ultrasound-mediated CavitationR01HL130046 · NHLBI · UNIVERSITY OF VIRGINIA · PI LINDNER, JONATHAN R · 2016 to 2023
$5.5M
Advanced Non-invasive Imaging in the Investigation of Aortic Stenosis PathobiologyR01HL165422 · NHLBI · UNIVERSITY OF VIRGINIA · PI Jonathan R Lindner · 2022 to 2026
$3.5M
NHLBI NIH HHS R01 HL130046NHLBI NIH HHS R35 HL145262NIH HHS NIH R01-HL078610NIH HHS NIH R01-HL165422NIH HHS R35-HL145262
6 · The paper itself

Abstract

backgroundThromboinflammation involving platelet adhesion to endothelial surface-associated von Willebrand factor (VWF) has been implicated in the accelerated progression of non-culprit plaques after MI. The aim of this study was to use arterial endothelial molecular imaging to mechanistically evaluate endothelial-associated VWF as a therapeutic target for reducing remote plaque activation after myocardial infarction (MI).

methodsHyperlipidemic mice deficient for the low-density lipoprotein receptor and Apobec-1 underwent closed-chest MI and were treated chronically with either: (i) recombinant ADAMTS13 which is responsible for proteolytic removal of VWF from the endothelial surface, (ii) N-acetylcysteine (NAC) which removes VWF by disulfide bond reduction, (iii) function-blocking anti-factor XI (FXI) antibody, or (iv) no therapy. Non-ischemic controls were also studied. At day 3 and 21, ultrasound molecular imaging was performed with probes targeted to endothelial-associated VWF A1-domain, platelet GPIbα, P-selectin and vascular cell adhesion molecule-1 (VCAM-1) at lesion-prone sites of the aorta. Histology was performed at day 21.

resultsAortic signal for P-selectin, VCAM-1, VWF, and platelet-GPIbα were all increased several-fold (p < 0.01) in post-MI mice versus sham-treated animals at day 3 and 21. Treatment with NAC and ADAMTS13 significantly attenuated the post-MI increase for all four molecular targets by > 50% (p < 0.05 vs. non-treated at day 3 and 21). On aortic root histology, mice undergoing MI versus controls had 2-4 fold greater plaque size and macrophage content (p < 0.05), approximately 20-fold greater platelet adhesion (p < 0.05), and increased staining for markers of platelet transforming growth factor-β1 signaling. Accelerated plaque growth and inflammatory activation was almost entirely prevented by ADAMTS13 and NAC. Inhibition of FXI had no significant effect on molecular imaging signal or plaque morphology.

conclusionsPlaque inflammatory activation in remote arteries after MI is strongly influenced by VWF-mediated platelet adhesion to the endothelium. These findings support investigation into new secondary preventive therapies for reducing non-culprit artery events after MI.

Indexed as

ADAMTS13 ProteinMyocardial Infarctionvon Willebrand FactorAcetylcysteineAnimalsAortaEndothelial CellsMaleMiceMice, Inbred C57BLMolecular ImagingPlaque, AtheroscleroticP-SelectinVascular Cell Adhesion Molecule-1AcetylcysteineADAMTS13 ProteinP-SelectinVascular Cell Adhesion Molecule-1von Willebrand FactorAtherosclerosisMolecular imagingPlateletsVon Willebrand factor

Identifiers

PMID38693516
PMCPMC11062912
OpenAlexW4396561680

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.